Sustained-Release Celecoxib from Incubated Acrylic Intraocular Lenses Suppresses Lens Epithelial Cell Growth in an Ex Vivo Model of Posterior Capsule Opacity
Davis, J. L., Yi, N. Y., Salmon, J. H., Charlton, A. N., Colitz, C. M. H., & Gilger, B. C. (2012, February 28). Journal of Ocular Pharmacology and Therapeutics, Vol. 28, pp. 359–368.
MeSH headings : Animals; Cataract Extraction; Celecoxib; Corneal Opacity / pathology; Corneal Opacity / prevention & control; Cyclooxygenase 2 Inhibitors / administration & dosage; Cyclooxygenase 2 Inhibitors / pharmacokinetics; Cyclooxygenase 2 Inhibitors / therapeutic use; Delayed-Action Preparations; Dogs; Epithelial Cells / drug effects; Epithelium / drug effects; Epithelium / growth & development; In Vitro Techniques; Lens, Crystalline / cytology; Lens, Crystalline / drug effects; Lens, Crystalline / growth & development; Lenses, Intraocular; Polymethyl Methacrylate; Posterior Capsule of the Lens / cytology; Posterior Capsule of the Lens / drug effects; Posterior Capsule of the Lens / pathology; Postoperative Complications / pathology; Postoperative Complications / prevention & control; Pyrazoles / administration & dosage; Pyrazoles / pharmacokinetics; Pyrazoles / therapeutic use; Sulfonamides / administration & dosage; Sulfonamides / pharmacokinetics; Sulfonamides / therapeutic use
topics (OpenAlex): Intraocular Surgery and Lenses; Anesthesia and Pain Management; Inflammatory mediators and NSAID effects
TL;DR:
A 4-day treatment of LCs with a concentration of 20 μM CXB may effectively prevent PCO and further studies are needed to determine whether C XB-incubated IOLs can effectively prevent the development of PCO in vivo.
(via
Semantic Scholar)
Sources: Web Of Science, NC State University Libraries